Shahram Bahmanyar

Follow

Generating author description...

Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ Marginal Structural Models and Causal Inference in Epidemiology 2000 James M. Robins
Miguel A. HernĂĄn
Babette Brumback
2
+ PDF Chat Targeted Maximum Likelihood Estimation for Dynamic and Static Longitudinal Marginal Structural Working Models 2014 Maya Petersen
Joshua Schwab
Susan Gruber
Nello Blaser
Michael Schomaker
Mark van der Laan
2
+ Analysing duration of episodes of pharmacological care: an example of antidepressant use in Danish general practice 2005 Anthony Gichangi
Morten Andersen
Jakob Kragstrup
Werner Vach
2
+ Comparison of dose standard units for drug utilisation studies 1996 Juan Merlo
A. Wessling
Arne Melander
2
+ Flexible modeling of the cumulative effects of time‐dependent exposures on the hazard 2009 Marie‐Pierre Sylvestre
MichaƂ Abrahamowicz
1
+ PDF Chat Randomized Trials Analyzed as Observational Studies 2013 Miguel A. HernĂĄn
Sonia HernĂĄndez–Dı́az
James M. Robins
1
+ Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data 2007 Soko Setoguchi
Daniel H. Solomon
Robert J. Glynn
E. Francis Cook
Raisa Levin
Sebastian Schneeweiß
1
+ PDF Chat Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs 2014 Til StĂŒrmer‎
Richard Wyss
Robert J. Glynn
M. Alan Brookhart
1
+ Time-dependent bias was common in survival analyses published in leading clinical journals 2004 Carl van Walraven
Darryl R. Davis
Alan J. Forster
George A. Wells
1
+ Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma 2012 Pasi Korhonen
Emmanuel Zuber
Michael Branson
Norbert Hollaender
Nigel A. Yateman
T. Katiskalahti
David Lebwohl
T Haas
1
+ Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context 2014 Nicholas Latimer
Keith R. Abrams
Paul C. Lambert
Michael J. Crowther
Allan Wailoo
James P. Morden
Ron Akehurst
Michael J. Campbell
1
+ Use of self‐controlled designs in pharmacoepidemiology 2014 Jesper Hallas
Anton PottegÄrd
1
+ Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men 2000 Miguel A. HernĂĄn
Babette Brumback
James M. Robins
1
+ A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies 1994 Tjeerd van Staa
Lucien Abenhaim
Hubert G. M. Leufkens
1
+ Adjusting for differential proportions of second‐line treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects 2004 Takuhiro Yamaguchi
Yasuo Ohashi
1
+ Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method 2014 Nicholas Latimer
Keith R. Abrams
Paul C. Lambert
Michael J. Crowther
Allan Wailoo
J.P. Morden
RL Akehurst
Michael J. Campbell
1
+ PDF Chat Structural Nested Cumulative Failure Time Models to Estimate the Effects of Interventions 2012 Sally Picciotto
Miguel A. HernĂĄn
John H. Page
Jessica G. Young
James M. Robins
1
+ Joint estimation of time‐dependent and non‐linear effects of continuous covariates on survival 2006 MichaƂ Abrahamowicz
Todd A. MacKenzie
1
+ PDF Chat Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence 2014 Christopher M. Booth
Ian F. Tannock
1
+ Relation between three classes of structural models for the effect of a time-varying exposure on survival 2009 Jessica G. Young
Miguel A. HernĂĄn
Sally Picciotto
James M. Robins
1
+ PDF Chat Adjusting overall survival for treatment switches: commonly used methods and practical application 2013 Claire Watkins
Xin Huang
Nicholas Latimer
Yiyun Tang
Elaine WRIGHT
1
+ Comparison of different methods to estimate prevalence of drug use by using pharmacy records 2001 Aukje K. Mantel‐Teeuwisse
Olaf H. Klungel
W. M. Monique Verschuren
A. J. Porsius
Anthonius de Boer
1
+ PDF Chat Immortal Time Bias in Pharmacoepidemiology 2007 Samy Suissa
1
+ Estimating causal effects of treatments in randomized and nonrandomized studies. 1974 Donald B. Rubin
1
+ PDF Chat Good practices for quantitative bias analysis 2014 Timothy L. Lash
Matthew P. Fox
Richard F. MacLehose
George Maldonado
Lawrence C. McCandless
Sander Greenland
1
+ PDF Chat Fallibility in estimating direct effects 2002 Stephen R. Cole
Miguel A. HernĂĄn
1
+ Methods for dealing with time‐dependent confounding 2012 Rhian Daniel
Simon Cousens
Bianca De Stavola
Michael G. Kenward
Jonathan A C Sterne
1
+ Structural Nested Failure Time Models 2014 James M. Robins
1
+ PDF Chat Doubly robust methods for handling confounding by cluster 2015 Johan Zetterqvist
Stijn Vansteelandt
Yudi Pawitan
Arvid Sjölander
1
+ PDF Chat Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma 2016 Jose Diaz
Cora N. Sternberg
Faisal Mehmud
Thomas E. Delea
Nicholas Latimer
Lini Pandite
Robert J. Motzer
1
+ Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method 2016 Jin Zhang
Cong Chen
1
+ PDF Chat Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials 2016 Eleanor J. Murray
Miguel A. HernĂĄn
1
+ PDF Chat Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. 2016 Miguel A. HernĂĄn
James M. Robins
1
+ The Quasi-cohort Approach in Pharmacoepidemiology 2014 Samy Suissa
1
+ Commentary 2012 Marshall M. Joffe
1
+ PDF Chat Biases in Randomized Trials 2016 Mohammad AlĂŹ Mansournia
Julian P. T. Higgins
Jonathan A C Sterne
Miguel A. HernĂĄn
1
+ PDF Chat Methodological comparison of marginal structural model, time‐varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture 2016 M. Sanni Ali
Rolf H. H. Groenwold
Svetlana V. Belitser
Patrick C. Souverein
Elisa Martín‐Merino
Nicolle M. Gatto
Consuelo Huerta
Helga GardarsdĂłttir
Kit C. B. Roes
Arno W. Hoes
1
+ PDF Chat Challenges in translating end points from trials to observational cohort studies in oncology 2016 Anne Gulbech Ording
Deirdre Cronin‐Fenton
VĂ©ra Ehrenstein
Timothy L. Lash
John Acquavella
Mikael RĂžrth
Henrik Toft SĂžrensen
1
+ PDF Chat Doubly Robust Estimation with the R Package drgee 2015 Johan Zetterqvist
Arvid Sjölander
1
+ Per-Protocol Analyses of Pragmatic Trials 2017 Miguel A. HernĂĄn
James M. Robins
1
+ PDF Chat Methods for time‐varying exposure related problems in pharmacoepidemiology: An overview 2017 Laura Pazzagli
Marie Linder
Mingliang Zhang
Emese VĂĄgĂł
Paul Stang
David T. Myers
Morten Andersen
Shahram Bahmanyar
1
+ The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data 2018 Miguel A. HernĂĄn
1
+ PDF Chat Assumptions made when preparing drug exposure data for analysis have an impact on results: <scp>A</scp>n unreported step in pharmacoepidemiology studies 2018 Stephen R. Pye
ThérÚse Sheppard
Rebecca M. Joseph
Mark Lunt
Nadyne Girard
Jennifer S. Haas
David W. Bates
David L. Buckeridge
Tjeerd van Staa
Robyn Tamblyn
1
+ Regression Using Fractional Polynomials of Continuous Covariates: Parsimonious Parametric Modelling 1994 Patrick Royston
Douglas G. Altman
1
+ PDF Chat Common misconceptions about validation studies 2020 Matthew P. Fox
Timothy L. Lash
Lisa M. Bodnar
1
+ PDF Chat Modeling the impact of hepatitis C viral clearance on end‐stage liver disease in an HIV co‐infected cohort with targeted maximum likelihood estimation 2013 Mireille E. Schnitzer
Erica E. M. Moodie
Mark J. van der Laan
Robert W. Platt
Marina B. Klein
1
+ PDF Chat Recent Developments in the Econometrics of Program Evaluation 2009 Guido W. Imbens
Jeffrey M. Wooldridge
1
+ Marginal Structural Models versus Structural nested Models as Tools for Causal inference 2000 James M. Robins
1
+ PDF Chat The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application 2015 Jennifer L. Lund
David B. Richardson
Til StĂŒrmer‎
1
+ <b>ipw</b>: An<i>R</i>Package for Inverse Probability Weighting 2011 Willem M. van der Wal
Ronald B. Geskus
1